These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 32554757)

  • 1. Bronchoscopic intratumoural therapies for non-small cell lung cancer.
    DeMaio A; Sterman D
    Eur Respir Rev; 2020 Jun; 29(156):. PubMed ID: 32554757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoural chemotherapy of lung cancer for diagnosis and treatment of draining lymph node metastasis.
    Celikoglu F; Celikoglu SI; Goldberg EP
    J Pharm Pharmacol; 2010 Mar; 62(3):287-95. PubMed ID: 20487210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoural administration and tumour tissue targeting of cancer immunotherapies.
    Melero I; Castanon E; Alvarez M; Champiat S; Marabelle A
    Nat Rev Clin Oncol; 2021 Sep; 18(9):558-576. PubMed ID: 34006998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bronchoscopic intratumoral injections of cisplatin and endostar as concomitants of standard chemotherapy to treat malignant central airway obstruction.
    Jiang W; Yang X; Wang X; Li Y; Yang X; Wang N; Yin B
    Postgrad Med J; 2022 Feb; 98(1156):104-112. PubMed ID: 33070116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
    Arbour KC; Riely GJ
    JAMA; 2019 Aug; 322(8):764-774. PubMed ID: 31454018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Career in Lung Cancer: Pushing Beyond Chemotherapy.
    Patil PD; Shepherd F; Johnson DH
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():583-589. PubMed ID: 31099660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
    Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
    Monteiro ID; Califano R; Mountzios G; de Mello RA
    Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
    Nagano T; Tachihara M; Nishimura Y
    Curr Cancer Drug Targets; 2019; 19(8):595-630. PubMed ID: 30526458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
    Dempke WC; Sellmann L; Fenchel K; Edvardsen K
    Anticancer Res; 2015 Nov; 35(11):5745-57. PubMed ID: 26503995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.
    Gridelli C; Ascierto PA; Barberis MC; Felip E; Garon EB; O'brien M; Senan S; Casaluce F; Sgambato A; Papadimitrakopoulou V; De Marinis F
    Expert Opin Biol Ther; 2016 Dec; 16(12):1479-1489. PubMed ID: 27650132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging therapeutic agents for advanced non-small cell lung cancer.
    Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
    J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection.
    Weill D; Mack M; Roth J; Swisher S; Proksch S; Merritt J; Nemunaitis J
    Chest; 2000 Oct; 118(4):966-70. PubMed ID: 11035664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.
    Meador CB; Hata AN
    Pharmacol Ther; 2020 Jun; 210():107522. PubMed ID: 32151666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
    Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
    J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy.
    Velez A; DeMaio A; Sterman D
    Front Immunol; 2023; 14():1203539. PubMed ID: 37671163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endobronchial intratumoral chemotherapy (EITC) followed by surgery in early non-small cell lung cancer with polypoid growth causing erroneous impression of advanced disease.
    Celikoglu SI; Celikoglu F; Goldberg EP
    Lung Cancer; 2006 Dec; 54(3):339-46. PubMed ID: 17045361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets.
    Sham NO; Zhao L; Zhu Z; Roy TM; Xiao H; Bai Q; Wakefield MR; Fang Y
    Anticancer Res; 2022 Jul; 42(7):3275-3284. PubMed ID: 35790251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
    Langer CJ
    Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.
    Qin A; Coffey DG; Warren EH; Ramnath N
    Cancer Med; 2016 Sep; 5(9):2567-78. PubMed ID: 27416962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.